Improving pharmacotherapy after myocardial infarction by group academic detailing using feedback data on a patient level

Pharmacotherapy

Volumn 26, Issue 2, 2006, Pages 254-259

  Van Der Elst, Menno E ^a,b,d   Bouvy, Marcel L ^a,b   De Blaey, Cornelis J ^a,c   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SIR Institute for Pharmacy Practice and Policy   (Netherlands)

^c WINAp   (Netherlands)

^d NONE   (Netherlands)

Author keywords

Group academic detailing; Intervention; Myocardial infarction; Peer review group; Pharmacotherapy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PEER REVIEW;

AGED; CARDIOVASCULAR AGENTS; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; PATIENT CARE TEAM; PEER REVIEW; PHARMACEUTICAL SERVICES; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; RECURRENCE;

EID: 32044439858     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.2.254     Document Type: Article

References (22)

1. van Eijk ME, Avorn J, Porsius AJ, de Boer A. Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing. BMJ 2001;322(7287):654-7.
2. Majumdar SR, Guirguis LM, Toth EL, Lewanczuk RZ, Lee TK, Johnson JA. Controlled trial of a multifaceted intervention for improving quality of care for rural patients with type 2 diabetes. Diabetes Care 2003;26(11):3061-6.
3. van Eijk MEC. Effects of outreach strategies on quality of pharmacotherapy [thesis]. Utrecht, the Netherlands: Utrecht University 2001.
4. van der Aalst A, van Oijen A, Stroo M, de Groot J. Quick scan rapidly presents an overview of conference quality [in Dutch]. Pharm Weekbl 2003;I38(49):I738-40.
5. Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in the Netherlands [dissertation]. Utrecht University, Utrecht, the Netherlands, 1993.
6. Statistics Netherlands. Main primary causes of death: statistics Netherlands (CBS), 2002. Available from http://statline.csb.nl. Accessed July 2, 2004.
7. American Heart Association. 2002 heart and stroke statistical update. Dallas, TX: American Heart Association, 2001.
8. Brady AJ, Oliver MA, Pittard JB. Secondary prevention in 24,431 patients with coronary heart disease: survey in primary care. BMJ 2001;322(7300):1463.
9. van der Elst ME, Cisneros-Gonzalez N, de Blaey CJ, Buurma H, de Boer A. Oral antithrombotic use among myocardial infarction patients. Ann Pharmacother 2003;37:143-6.
10. Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey BMJ 2001;322(7290):832-6.
11. Martinez M, Agusti A, Arnau JM, Vidai X, Laporte JR. Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period. Eur J Clin Pharmacol 1998;54(3):203-8.
12. Barron HV, Michaels AD, Maynard C, Every NR. Use of angiotensin- converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the national registry of myocardial infarction 2. J Am Coll Cardiol 1998;32(2):360-7.
13. Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the Medicare health care quality improvement program. Arch Intern Med 2003;163(12):1430-9.
14. de Velasco JA, Cosin J, de Oya M, de Teresa E. Intervention program to improve secondary prevention of myocardial infarction: results of the PRESENTE (early secondary prevention) study. Rev Esp Cardiol 2004;57(2):146-54.
15. Soumerai SB, Avorn J. Principles of educational outreach (academic detailing) to improve clinical decision making. JAMA 1990;263(4):549-56.
16. van der Elst ME, Buurma H, Bouvy ML, de Boer A. Drug therapy for prevention of recurrent myocardial infarction. Ann Pharmacother 2003;37(10):1465-77.
17. Simoons ML, Casparie AF. Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels: third consensus for cholesterol. Consensus working group, CBO [in Dutch]. Ned Tijdschr Geneeskd 1998;142(38):2096-101.
18. Dutch College of General Practitioners. Cholesterol guideline, 1999 [in Dutch]. Available from www.nhg.artsennet.nl/upload/iou/standaarden/m20/start. htm. Accessed July 2, 2004.
19. Figueiras A, Sastre I, Tato F, et al. One-to-one versus group sessions to improve prescription in primary care: a pragmatic randomized controlled trial. Med Care 2001;39(2):158-67.
20. Diwan VK, Wahlstrom R, Tomson G, Beermann B, Sterky G, Eriksson B. Effects of group detailing on the prescribing of lipid-lowering drugs: a randomized controlled trial in Swedish primary care. J Clin Epidemiol 1995;48(5):705-11.
21. Lundborg CS, Wahlstrom R, Oke T, Tomson G, Diwan VK. Influencing prescribing for urinary tract infection and asthma in primary care in Sweden: a randomized controlled trial of an interactive educational intervention. J Clin Epidemiol 1999;52(8):801-12.
22. Santoso B. Small group intervention vs formal seminar for improving appropriate drug use. Soc Sci Med 1996;42(8):1163-8.